Ultrasound contrast agent delivered per os first diagnoses pharyngoesophageal tumour

E Antypa; D D Cokkinos; I Kalogeropoulos; D Tomais; P N Piperopoulos

doi:10.5334/jbr-btr.211

Ultrasound contrast agent delivered per os first diagnoses pharyngoesophageal tumour

JBR-BTR. 2013 Mar-Apr;96(2):69-71. doi: 10.5334/jbr-btr.211.

Authors

E Antypa¹, D D Cokkinos, I Kalogeropoulos, D Tomais, P N Piperopoulos

Affiliation

¹ Radiology Department, Evangelismos Hospital, Athens, Greece.

PMID: 23847823
DOI: 10.5334/jbr-btr.211

Abstract

Oral administration of ultrasound contrast agents has been described very little so far in medical literature. These agents are mainly administered intravenously and, less commonly, intracavitarily. We present the case of a patient with a cervical mass in whom sonographic examination with per os administration of SonoVue led to the diagnosis of a pharyngoesophageal tumour. The diagnosis was confirmed on barium swallow and endoscopy-guided biopsy.

Publication types

Case Reports

MeSH terms

Administration, Oral
Adult
Biopsy
Carcinoma, Squamous Cell / diagnostic imaging*
Contrast Media / administration & dosage*
Diagnosis, Differential
Esophageal Neoplasms / diagnostic imaging*
Esophagoscopy
Humans
Male
Pharyngeal Neoplasms / diagnostic imaging*
Phospholipids / administration & dosage*
Sulfur Hexafluoride / administration & dosage*
Ultrasonography

Substances

Contrast Media
Phospholipids
contrast agent BR1
Sulfur Hexafluoride